Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy

被引:532
作者
Eggener, Scott E. [3 ]
Scardino, Peter T. [4 ]
Walsh, Patrick C. [5 ]
Han, Misop [5 ]
Partin, Alan W. [5 ]
Trock, Bruce J. [5 ]
Feng, Zhaoyong [5 ]
Wood, David P. [6 ]
Eastham, James A. [4 ]
Yossepowitch, Ofer [7 ]
Rabah, Danny M. [8 ]
Kattan, Michael W.
Yu, Changhong [2 ]
Klein, Eric A. [1 ]
Stephenson, Andrew J. [1 ]
机构
[1] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44195 USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
[3] Univ Chicago, Med Ctr, Urol Sect, Chicago, IL 60637 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[5] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA
[6] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA
[7] Rabin Med Ctr, Petah Tiqwa, Israel
[8] King Saud Univ, Dept Surg, Div Urol, Princess Johara Alibrahim Ctr Canc Res, Riyadh, Saudi Arabia
基金
美国国家卫生研究院;
关键词
prostate; prostatic neoplasms; prostatectomy; mortality; nomograms; BIOCHEMICAL RECURRENCE; SALVAGE RADIOTHERAPY; RADIATION-THERAPY; NATURAL-HISTORY; SURVIVAL; RISK; NOMOGRAM; OUTCOMES; TRIAL; MEN;
D O I
10.1016/j.juro.2010.10.057
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Long-term prostate cancer specific mortality after radical prostatectomy is poorly defined in the era of widespread screening. An understanding of the treated natural history of screen detected cancers and the pathological risk factors for prostate cancer specific mortality are needed for treatment decision making. Materials and Methods: Using Fine and Gray competing risk regression analysis we modeled clinical and pathological data, and followup information on 11,521 patients treated with radical prostatectomy at a total of 4 academic centers from 1987 to 2005 to predict prostate cancer specific mortality. The model was validated on 12,389 patients treated at a separate institution during the same period. Median followup in the modeling and validation cohorts was 56 and 96 months, respectively. Results: The overall 15-year prostate cancer specific mortality rate was 7%. Primary and secondary Gleason grade 4-5 (each p < 0.001), seminal vesicle invasion (p < 0.001) and surgery year (p = 0.002) were significant predictors of prostate cancer specific mortality. A nomogram predicting 15-year prostate cancer specific mortality based on standard pathological parameters was accurate and discriminating with an externally validated concordance index of 0.92. When stratified by patient age at diagnosis, the 15-year prostate cancer specific mortality rate for pathological Gleason score 6 or less, 3 + 4, 4 + 3 and 8-10 was 0.2% to 1.2%, 4.2% to 6.5%, 6.6% to 11% and 26% to 37%, respectively. The 15-year prostate cancer specific mortality risk was 0.8% to 1.5%, 2.9% to 10%, 15% to 27% and 22% to 30% for organ confined cancer, extraprostatic extension, seminal vesicle invasion and lymph node metastasis, respectively. Only 3 of 9,557 patients with organ confined, pathological Gleason score 6 or less cancer died of prostate cancer. Conclusions: Poorly differentiated cancer and seminal vesicle invasion are the prime determinants of prostate cancer specific mortality after radical prostatectomy. The prostate cancer specific mortality risk can be predicted with remarkable accuracy after the pathological features of prostate cancer are known.
引用
收藏
页码:869 / 875
页数:7
相关论文
共 25 条
[1]   Prostate cancer and the Will Rogers phenomenon [J].
Albertsen, PC ;
Hanley, JA ;
Barrows, GH ;
Penson, DF ;
Kowalczyk, PDH ;
Sanders, MM ;
Fine, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253
[2]   20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[3]   Radical prostatectomy versus watchful waiting in localized prostate cancer:: the Scandinavian Prostate Cancer Group-4 randomized trial [J].
Bill-Axelson, Anna ;
Holmberg, Lars ;
Filen, Frej ;
Ruutu, Mirja ;
Garmo, Hans ;
Busch, Christer ;
Nordling, Stig ;
Haggman, Michael ;
Andersson, Swen-Olof ;
Bratell, Stefan ;
Spangberg, Anders ;
Palmgren, Juni ;
Adami, Hans-Olov ;
Johansson, Jan-Erik .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (16) :1144-1154
[4]   Long-term outcome among men with conservatively treated localised prostate cancer [J].
Cuzick, J. ;
Fisher, G. ;
Kattan, M. W. ;
Berney, D. ;
Oliver, T. ;
Foster, C. S. ;
Moller, H. ;
Reuter, V. ;
Fearn, P. ;
Eastham, J. ;
Scardino, P. .
BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1186-1194
[5]   Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].
D'Amico, AV ;
Moul, JW ;
Carroll, PR ;
Sun, L ;
Lubeck, D ;
Chen, MH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383
[6]   Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy [J].
D'Amico, AV ;
Chen, MH ;
Roehl, KA ;
Catalona, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :125-135
[7]   Pathologic stage migration has slowed in the late PSA era [J].
Dong, Fel ;
Reuther, Alwyn M. ;
Magi-Galluzzi, Cristina ;
Zhou, Ming ;
Kupelian, Patrick A. ;
Klein, Eric A. .
UROLOGY, 2007, 70 (05) :839-842
[8]   Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context [J].
Draisma, Gerrit ;
Etzioni, Ruth ;
Tsodikov, Alex ;
Mariotto, Angela ;
Wever, Elisabeth ;
Gulati, Roman ;
Feuer, Eric ;
de Koning, Harry .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (06) :374-383
[9]   The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [J].
Epstein, JI ;
Allsbrook, WC ;
Amin, MB ;
Egevad, LL ;
Bastacky, S ;
Beltrán, AL ;
Berner, A ;
Billis, A ;
Boccon-Gibod, L ;
Cheng, L ;
Civantos, F ;
Cohen, C ;
Cohen, MB ;
Datta, M ;
Davis, C ;
Delahunt, B ;
Delprado, W ;
Eble, JN ;
Foster, CS ;
Furusato, M ;
Gaudin, PB ;
Grignon, DJ ;
Humphrey, PA ;
Iczkowski, KA ;
Jones, EC ;
Lucia, S ;
McCue, PA ;
Nazeer, T ;
Oliva, E ;
Pan, CC ;
Pizov, G ;
Reuter, V ;
Samaratunga, H ;
Sebo, T ;
Sesterhenn, I ;
Shevchuk, M ;
Srigley, JR ;
Suzigan, S ;
Takahashi, H ;
Tamboli, P ;
Tan, PH ;
Têtu, B ;
Tickoo, S ;
Tomaszewski, JE ;
Troncoso, P ;
Tsuzuki, T ;
True, LD ;
van der Kwast, T ;
Wheeler, TM ;
Wojno, KJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1228-1242
[10]   Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy [J].
Freedland, SJ ;
Humphreys, EB ;
Mangold, LA ;
Eisenberger, M ;
Dorey, FJ ;
Walsh, PC ;
Partin, AW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (04) :433-439